Phage therapy
- PMID: 38821504
- DOI: 10.1302/0301-620X.106B6.BJJ-2023-0878.R2
Phage therapy
Conflict of interest statement
J. D. Jones reports grants or contracts from the Tayside Health Fund Charity, related to this study, and is director of the non-profit company UK Phage Therapy, which was not involved in any aspect of this work. R. M. D. Meek reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Palacademy and DePuy, both of which are unrelated to this study, as is a member of the editorial board of The Bone & Jone Journal.
References
-
- Moore AJ , Wylde V , Whitehouse MR , et al. Development of evidence-based guidelines for the treatment and management of periprosthetic hip infection . Bone Jt Open . 2023 ; 4 ( 4 ): 226 – 233 . 10.1302/2633-1462.44.BJO-2022-0155.R1 37051823
-
- Gibb BP , Hadjiargyrou M . Bacteriophage therapy for bone and joint infections . Bone Joint J . 2021 ; 103-B ( 2 ): 234 – 244 . 10.1302/0301-620X.103B2.BJJ-2020-0452.R2 33517726
-
- Murray CJL , Ikuta KS , Sharara F . Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis . Lancet . 2022 ; 399 ( 10325 ): 629 – 655 . 10.1016/S0140-6736(21)02724-0 35065702
-
- No authors listed . Tackling drug-resistant infections globally: final report and recommendations . The Review on Antimicrobial Resistance . 2016 . https://amr-review.org/sites/default/files/160525_Final%20paper_with%20c... ( date last accessed 17 April 2024 ).
-
- Dedrick RM , Smith BE , Cristinziano M , et al. Phage therapy of Mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant Mycobacterial disease . Clin Infect Dis . 2023 ; 76 ( 1 ): 103 – 112 . 10.1093/cid/ciac453 35676823
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources